What should be considered during epicutaneous patch testing?
DC Element | Wert | Sprache |
---|---|---|
dc.contributor.author | Brans, Richard | |
dc.contributor.author | Mahler, Vera | |
dc.date.accessioned | 2023-07-12T06:59:20Z | - |
dc.date.available | 2023-07-12T06:59:20Z | - |
dc.date.issued | 2023 | |
dc.identifier.issn | 2197-0378 | |
dc.identifier.uri | http://osnascholar.ub.uni-osnabrueck.de/handle/unios/72044 | - |
dc.description | Cited by: 0; All Open Access, Hybrid Gold Open Access | |
dc.description.abstract | Indications for epicutaneous patch testing include the detection or exclusion of allergic contact dermatitis of the skin, transitional mucosa or oral mucosa, suspected delayed-type immune reactions to ingredients of implants, and certain drug reactions (maculopapular exanthema, symmetrical drug-related intertriginous and flexural exanthema [SDRIFE], acute generalized exanthematous pustulosis [AGEP], and fixed drug eruption). When available, allergen preparations that have been pharmaceutically tested and that are approved or marketable as medicinal products should be used. Existing diagnostic gaps can be closed by testing the patient's own materials in asuitable preparation. Interferences of ultraviolet (UV) light exposure or drugs with patch test reactions have to be considered. In addition to the reading after 48 h and 72 h, afurther reading between day7 (168 h) and day10 (240 h) is useful, since about 15% of the positive test reactions remain undetected without this late reading. All positive patch test reactions considered allergic must be evaluated with regard to their clinical relevance based on existing exposures. © 2023, The Author(s). | |
dc.language.iso | en | |
dc.publisher | Springer Medizin | |
dc.relation.ispartof | Allergo Journal International | |
dc.subject | allergen | |
dc.subject | Allergic contact dermatitis | |
dc.subject | antihistaminic agent | |
dc.subject | benzoyl peroxide | |
dc.subject | child | |
dc.subject | chlorhexidine | |
dc.subject | chloroacetamide | |
dc.subject | Contact allergy | |
dc.subject | contact dermatitis | |
dc.subject | corticosteroid | |
dc.subject | drug competition | |
dc.subject | Drug interference | |
dc.subject | dupilumab | |
dc.subject | erythema | |
dc.subject | formaldehyde | |
dc.subject | glucocorticoid | |
dc.subject | human | |
dc.subject | immunity | |
dc.subject | immunosuppressive treatment | |
dc.subject | light exposure | |
dc.subject | maculopapular rash | |
dc.subject | mercaptobenzothiazole | |
dc.subject | neomycin | |
dc.subject | patch test | |
dc.subject | povidone iodine | |
dc.subject | prednisolone | |
dc.subject | Problem allergen | |
dc.subject | propylene glycol | |
dc.subject | pruritus | |
dc.subject | rash | |
dc.subject | Relevance | |
dc.subject | Review | |
dc.subject | skin biopsy | |
dc.subject | skin defect | |
dc.subject | skin irritation | |
dc.subject | skin manifestation | |
dc.subject | triethanolamine | |
dc.subject | ultraviolet radiation | |
dc.subject | vaccination | |
dc.title | What should be considered during epicutaneous patch testing? | |
dc.type | review | |
dc.identifier.doi | 10.1007/s40629-023-00243-y | |
dc.identifier.scopus | 2-s2.0-85147308400 | |
dc.identifier.url | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85147308400&doi=10.1007%2fs40629-023-00243-y&partnerID=40&md5=80596dfcb8a8b1b6f6442245977f046a | |
dc.description.volume | 32 | |
dc.description.issue | 3 | |
dc.description.startpage | 77 – 82 | |
dcterms.isPartOf.abbreviation | Allergo J. Int. | |
local.import.remains | affiliations : Department of Dermatology, Environmental Medicine and Health Theory, University of Osnabrück, Osnabrück, Germany; Institute for interdisciplinary Dermatological Prevention and Rehabilitation (iDerm), University of Osnabrück, Am Finkenhügel 7a, Osnabrück, 49076, Germany; Allergology Division, Paul-Ehrlich-Institut, Langen, Germany | |
local.import.remains | correspondence_address : R. Brans; Institute for interdisciplinary Dermatological Prevention and Rehabilitation (iDerm), University of Osnabrück, Osnabrück, Am Finkenhügel 7a, 49076, Germany; email: rbrans@uos.de | |
local.import.remains | publication_stage : Final | |
crisitem.author.dept | Universität Osnabrück | - |
crisitem.author.orcid | 0000-0002-1245-024X | - |
Seitenaufrufe
2
Letzte Woche
0
0
Letzter Monat
0
0
geprüft am 01.06.2024